Overview

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB) patients.
Phase:
Phase 1
Details
Lead Sponsor:
Dynavax Technologies Corporation
Treatments:
Entecavir